Welcome to our dedicated page for Biomarin Pharmaceutical news (Ticker: BMRN), a resource for investors and traders seeking the latest updates and insights on Biomarin Pharmaceutical stock.
BioMarin Pharmaceutical Inc. develops and commercializes medicines for rare genetic diseases, with recurring news centered on commercial portfolio performance, regulatory approvals, clinical data and business development. Company updates commonly reference therapies for achondroplasia, phenylketonuria, hemophilia, mucopolysaccharidosis and lysosomal storage diseases, including VOXZOGO, PALYNZIQ, GALAFOLD and POMBILITI + OPFOLDA.
BioMarin news also covers financial results, guidance, acquisition integration, debt financing and governance changes. Clinical and regulatory announcements focus on genetically defined conditions, skeletal disorders, enzyme-based therapies and investigational rare-disease programs such as DMX-200 for focal segmental glomerulosclerosis.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BioMarin Pharmaceutical reported a 15% increase in total revenues for Q1 2023, reaching $596.4 million, driven by strong sales of VOXZOGO. This product saw revenue growth of 346%, indicating robust market uptake in Japan and Brazil. The company's enzyme product revenues also contributed positively, with ALDURAZYME showing a notable increase.
However, GAAP net income decreased to $50.9 million from $120.8 million in Q1 2022 due to the absence of a previous one-time gain. The company adjusted its revenue guidance for ROCTAVIAN, lowering expectations to between $50 million and $150 million, while reaffirming overall revenue guidance for 2023 between $2.375 billion and $2.5 billion.
BioMarin's operational focus includes preparations for ROCTAVIAN's launch in the U.S., with a PDUFA target action date set for June 30, 2023.